Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-38 |
filingDate |
2014-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_333004043aa3c419ea2efffe31ab6453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca4b2cdeb778b4cdce363fee6ead436e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_728575337539f04f1c820e79242fbcf9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9349e341e392af960aff64a5d03df9a1 |
publicationDate |
2015-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2015069745-A2 |
titleOfInvention |
Tumors expressing igg1 fc induce robust cd8 cell responses |
abstract |
A lymphoma cell line was engineered to express surface IgGl Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgGl-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgGl-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgGl can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen. |
priorityDate |
2013-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |